Atopic Dermatitis: Global and China Landscape
Atopic dermatitis treatment is moving into a new phase, where convenience, safety and access matter as much as efficacy.
- Crowded Pipeline: China has one approved home-grown IL-4Rα antibody and seven more under regulatory review, making it a major hub of late-stage development.
- New Differentiators: With few head-to-head trials to rank efficacy, longer dosing intervals, faster itch relief and lighter monitoring are increasingly what sets therapies apart.
- Access Decides Uptake: National reimbursement listing (NRDL), provincial coverage and whether patients stay on treatment will shape real-world adoption.
See how ten targets compare, from IL-4Rα to OX40 and TYK2.
Download the Full Report
1
Anytime Access
Praesent porttitor, nulla vitae posuere iaculis, arcu nisl dignissim dolor, a pretium mi sem ut ipsum. Fusce fermentum.
2
Add-ons Compatibility
Praesent porttitor, nulla vitae posuere iaculis, arcu nisl dignissim dolor, a pretium mi sem ut ipsum. Fusce